Share
Dr. Stephen Doberstein
Invea Therapeutics, Inc., a biotechnology company leveraging artificial intelligence (AI), GenAI, and machine learning (ML) to develop breakthrough therapies for immune-mediated inflammatory diseases (IMIDs), announced the appointment of Stephen Doberstein, Ph.D., to its Board of Directors.
Dr. Doberstein is a seasoned biotech executive with over 30 years of experience in drug discovery, development, and corporate financial strategy. He has held senior leadership roles across the biopharmaceutical industry, guiding multiple drug programs through clinical trials and contributing to advancements in oncology, immunology, and inflammation. His expertise in both early- and late-stage drug development, along with corporate financing, will be instrumental as Invea advances its pipeline into Phase 2 clinical development.
Dr. Doberstein joins a distinguished board of experts in biotechnology, AI-driven drug discovery, and clinical development, further strengthening Invea’s leadership as it moves toward mid-stage clinical execution.
